Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics

Chrisanna Dobrowolski; Edward G Clark; Manish M Sood

doi:10.1007/s11239-016-1437-1

Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics

J Thromb Thrombolysis. 2017 Feb;43(2):241-247. doi: 10.1007/s11239-016-1437-1.

Authors

Chrisanna Dobrowolski¹, Edward G Clark², Manish M Sood^{3

4}

Affiliations

¹ Division of Internal Medicine, University of Ottawa, Ottawa, Canada.
² Division of Nephrology, University of Ottawa, Ottawa, Canada.
³ Division of Nephrology, University of Ottawa, Ottawa, Canada. Msood@toh.on.ca.
⁴ The Ottawa Hospital Research Institute, The Ottawa Hospital, Civic campus, 2-014 Administrative Services Building, 1053 Carling Avenue, Box 693, Ottawa, ON, K1Y 4E9, Canada. Msood@toh.on.ca.

PMID: 27738784
DOI: 10.1007/s11239-016-1437-1

Abstract

The worldwide prevalence of chronic kidney disease is 10-15 % of the adult population, is rising and increases susceptibility to venous thromboembolism (VTE). In this narrative review we discuss the underlying evidence behind the association of VTE/CKD and examine the role of worsening CKD stage, proteinuria, and the risk of recurrent VTE. As CKD may alter therapeutic options we discuss the role of emerging therapies, the non-vitamin K oral anticoagulants (NOAC), in the treatment of VTE.

Keywords: Albuminuria; Chronic kidney disease; Epidemiology; Non-vitamin K antagonist oral anticoagulants; Venous thromboembolism.

Publication types

Review

MeSH terms

Anticoagulants / therapeutic use
Humans
Proteinuria / complications
Renal Insufficiency, Chronic / complications
Renal Insufficiency, Chronic / drug therapy
Renal Insufficiency, Chronic / epidemiology*
Severity of Illness Index
Venous Thromboembolism / drug therapy
Venous Thromboembolism / epidemiology*
Venous Thromboembolism / etiology

Substances

Anticoagulants